Vera Therapeutics, Inc. (VERA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$35.89+2.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VERA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -58.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
VERA — officer change
Dated 2026-07-09
Chief Regulatory Officer — William Turner: William Turner transitions to Special Advisor for Regulatory Affairs with Nancy Bowman, M.D., Ph.D. succeeding as Chief Regulatory Officer.
Why it matters: Rising cash burn may worry people about Vera's money situation and funding.
Worry ifCash burn goes down from the current $106.5 million in operating activities.
Less concerning ifCash burn goes up beyond current levels, showing worse financial health.
Why it matters: This submission is key for getting full approval of TRUTAKNA. It shows commitment to rules.
Supportive ifVera sends the Biologics License Application to the FDA on time.
Worry ifThe submission is late or missing. This may mean there are regulatory problems.
Why it matters: Delays in the BLA submission could hurt the launch and affect investor feelings.
Worry ifManagement confirms that the BLA submission is on track for Q4 2025.
Less concerning ifManagement says there is a delay in the BLA submission timeline.
Why it matters: Early results may show atacicept works well for more IgAN patients. Good results can help investors.
Watch forEarly results from the PIONEER trial show atacicept works well in more IgAN patients.
Also watch forEarly results from the PIONEER trial show no clear signs of effectiveness or safety issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$203 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $464 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,810 loss on $10,000 · 48.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Continued increases in losses signal challenges in managing costs and cash burn. This could raise concerns about financial health.
Worry ifOperating losses increase beyond $121M in Q1 2026.
Less concerning ifOperating losses drop or stay below $121M in the next quarter.
Why it matters: These results are key for the full approval of atacicept in IgA Nephropathy. A positive outcome would support the launch plans.
Supportive ifThe eGFR results show a clear improvement in patients treated with atacicept.
Worry ifThe eGFR results do not show a clear improvement compared to the control group.
Why it matters: Monitoring net losses will show how well the company manages expenses during the launch phase. Increasing losses could raise concerns.
Worry ifNet losses are lower or stable compared to past quarters. This shows better cost management.
Less concerning ifNet losses rise a lot, suggesting worse financial health during the launch.
Why it matters: The FDA's decision will determine if atacicept can be sold for IgAN. This is crucial for Vera's future revenue.
Supportive ifThe FDA gives quick approval for atacicept by the PDUFA date.
Worry ifFDA denies approval or delays the decision beyond July 7, 2026.
Why it matters: High losses mean it is hard to manage cash. This may hurt investor confidence.
Worry ifNet losses in Q2 exceed $121M, showing worsening financial health.
Less concerning ifNet losses in Q2 are less than or equal to $121M, indicating better cash management.
Why it matters: The success of the launch will determine market acceptance and revenue potential. Early reception is key for long-term growth.
Supportive ifNephrologists give good feedback. Early sales show strong demand in the market.
Worry ifWeak early sales and bad feedback from providers suggest a poor market response.
Why it matters: Results will support the case for full approval of TRUTAKNA. Positive outcomes could strengthen market confidence.
Supportive ifThe final analysis from the ORIGIN 3 trial shows that kidney function is better.
Worry ifResults show no clear improvement. This raises doubts about how well TRUTAKNA works.
Why it matters: A successful launch is key for making money and market position in IgAN.
Supportive ifStrong sales or good market reactions after the TRUTAKNA launch.
Worry ifBad market feedback or lower sales numbers after the launch.
Why it matters: The results will help get full approval for TRUTAKNA. This is key for its market.
Supportive ifThe ORIGIN 3 trial had positive results. It shows TRUTAKNA works well for IgAN patients.
Worry ifThe results show it does not work well. They did not meet the main goal.
Why it matters: The FDA's choice will decide if TRUTAKNA gets full approval for IgAN.
Supportive ifFDA grants full approval for TRUTAKNA based on the sBLA submission.
Worry ifFDA denies or delays approval of the sBLA submission.
Why it matters: Rising losses could signal challenges in managing costs during the launch phase.
Worry ifNet losses increase beyond $109.5 million in Q3 2026.
Less concerning ifNet losses decrease or stabilize below $109.5 million in Q3 2026.